Open access · CC-BY
via OpenAlex
A Clinically Adjusted Transcriptomic Signature for Survival Stratification in High-Grade Serous Ovarian Cancer
Aicha Lakhssassi, Mohcine Bennani Mechita, Joaira Bakkach
JCO Global Oncology · 2026
Abstract
PURPOSE High-grade serous ovarian cancer (HGSOC) remains the most lethal gynecologic malignancy, and clinical outcomes vary substantially even among patients with apparently favorable surgical cytoreduction. Improved molecular risk stratification may help identify patients at higher risk despite standard clinical prognostic features. Using publicly available transcriptomic and clinical data, we developed a compact transcriptomic signature for overall survival and assessed whether it added prognostic information beyond age, stage, and residual disease. METHODS Using TCGA-OV RNA-seq and clinical data (n = 416 HGSOC), we built a parsimonious survival signature by variance filtering, univariable Cox screening, 5-fold cross-validated LASSO-Cox, and multivariable Cox pruning. Performance was assessed on a held-out 30% test partition, in multivariable Cox adjusted for age, stage, and residual disease, and within debulking strata. Robustness was tested by 100-bootstrap resampling and consensus across Random Forest, Gradient Boosting, and L1-logistic regression. Differential expression in two additional HGSOC cohorts (n = 165 tumors) supported biological interpretation. RESULTS A nine-gene signature emerged: PRSS16, CTXN2, FCRLA (protective); PI3, LILRA2, LCN6, RNF103-CHMP3, KLK3, MTRNR2L8 (adverse). Held-out test: HR 2.15 (95% CI 1.35–3.43, p = 1.2×10 -3 ); 5-year time-dependent AUC 0.69. In multivariable Cox (n = 363), the signature was independently associated with survival (HR 1.76 per SD, P < 1×10 -10 ) and improved discrimination from C-index 0.62 to 0.69 (likelihood-ratio χ 2 = 69.6). Prognostic value was retained within R0 (no macroscopic residual) patients (HR 1.57, P = 3×10 -3 ; median survival 7.7 vs 3.8 years). Four genes (PRSS16, LILRA2, LCN6, PI3) ranked in the top 15 of all four orthogonal methods. CONCLUSION This exploratory nine-gene transcriptomic signature, derived from publicly available HGSOC transcriptomic and clinical data, stratifies overall survival and adds prognostic information beyond stage and surgical debulking. Its retained value among optimally debulked patients addresses a clinically important setting where additional risk stratification is needed. The signature reflects established TLS–mesenchymal tumor biology and nominates relatively understudied components, including CTXN2, RNF103-CHMP3, and MTRNR2L8, for orthogonal validation. External survival validation is required before clinical translation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1200/go-26-10000
- Canonical
- link ↗
- Fetched
- 2026-11-16 MST
Cite this
APA
Lakhssassi, A., Mechita, M.B., & Bakkach, J. (2026). A Clinically Adjusted Transcriptomic Signature for Survival Stratification in High-Grade Serous Ovarian Cancer. <em>JCO Global Oncology</em>. https://doi.org/10.1200/go-26-10000
Vancouver
Lakhssassi A, Mechita MB, Bakkach J. A Clinically Adjusted Transcriptomic Signature for Survival Stratification in High-Grade Serous Ovarian Cancer. JCO Global Oncology. 2026. doi:10.1200/go-26-10000.
BibTeX
@article{aicha2026AClini,
title = {A Clinically Adjusted Transcriptomic Signature for Survival Stratification in High-Grade Serous Ovarian Cancer},
author = {Aicha Lakhssassi and Mohcine Bennani Mechita and Joaira Bakkach},
journal = {JCO Global Oncology},
year = {2026},
doi = {10.1200/go-26-10000},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2026
Open access · CC-BY
A Novel Partial EMT-Associated Transcriptomic Signature for Prognostic Stratification in Ovarian Cancer
BMC Bioinformatics 2026
Open access · CC-BY
A knowledge graph-guided transcriptomic framework identifies a 20-gene prognostic signature for cervical cancer
Wales Cancer Trials Unit 2011
Open access · US-GOV
A Pilot Clinical Trial Looking at the Effect on Lung Cancer Diagnosis of Giving a CXR to Smokers Aged Over 60 With Chest Symptoms
bioRxiv (Cold Spring Harbor Laboratory) 2024
Preprint · CC-BY
Applicability of epigenetic age models to next-generation methylation arrays
Journal of Clinical Oncology 2026
Citation only
Transcriptomic signature of temozolomide treatment-effect heterogeneity in IDH-wildtype glioblastoma.
Diabetology & Metabolic Syndrome 2020
Open access · CC-BY